Top Trends in Antibacterial Drugs,B-Lactams also Likely to Dominate in Forthcoming Years


Published Date : Apr 11, 2016

The utilization of antibacterial drugs is rising exponentially. These drugs have been utilized both in human beings and animals and inhibit the reproduction of bacteria. In some cases, these drugs kill the bacteria entirely, hence preventing them from causing infections. Nowadays, it is extremely difficult to treat numerous diseases and infections imposed by bacteria including tuberculosis, pneumonia, legionellosis, and diphtheria. While a number of trends are impacting the development of the antibacterial drugs market, some of the top trends influencing the market are as follows:

  • ?-Lactams, Most Commonly Used Antibacterial Drug Class Globally: The top most common drugs utilized globally include tetracyclines, ?-Lactams, macrolides, phenicols, sulfonamides, quinolones, aminoglycosides, and miscellaneous antibacterials. Amongst these, approximately 58% of the share was taken by ?-Lactams in 2014. On the other hand, the utilization of quinolones was also huge but not as much as ?-Lactams. The segment of quinolones held a share of 17% in the market in the same year. In addition, this segment is losing its share year by year and it has been predicted that this segment will exhibit a negative growth rate from 2015 to 2023. 
  • Companies Operating in Antibacterial Drugs Market Profiting from Aging Population: The growing aging population is amongst the key factors driving the development of the market for antibacterial drugs. This growth in the aging population is poised to be fuelled by the increasing demand for miscellaneous antibacterials, which is the segment predicted to rise the highest growth rate globally.
  • Market Growth may Slow Down due to Decreasing Profitability of Top Antibacterial Drug Brands owing to Patent Expiries:  The expiry of patents of top drug name brands can result in the decreasing growth of the market for antibacterial drugs. In addition¸ the soaring count of bacterial strains being resistant to the already present drug formulation is also hampering the growth of the market. This will result in the introduction of new research and development programs for regaining or maintaining a competitive edge in the market for antibacterial drugs.

On the other hand, the preplanned commercialization of a large number of antibacterial agents in forthcoming years is expected to bring in new growth opportunities in the market in the coming years. Some of these formulations are solithromycin (Cempra, Inc.), MK-3415A (Merck & Co.), and surotomycin (Merck & Co.), among others.